You are here

FDA Considers Labeling Update for Schizophrenia Drug Brexpiprazole (Rexulta)

Application seeks approval for maintenance treatment of adults with schizophrenia

The FDA has accepted for review a supplemental new drug application (sNDA) for a proposed labeling update of brexpiprazole (Rexulta, Otsuka/Lundbeck) for the maintenance treatment of adults with schizophrenia. The Prescription Drug User Fee Act (PDUFA) date is September 23, 2016.

The sNDA was supported by results from a 52-week randomized withdrawal trial in adults (18 to 65 years of age) with schizophrenia. Patients were stabilized on brexpiprazole and were then randomly assigned to continue therapy with brexpiprazole (n = 96) or placebo (n = 104). The study’s primary endpoint was the time from randomization to relapse. In a prespecified interim analysis, the study demonstrated a significantly longer time to relapse in the brexpiprazole group (1 to 4 mg/day) compared with the placebo group. The trial was terminated early because maintenance of efficacy had been demonstrated (P < 0.0001, final analysis).

The mechanism of action of brexpiprazole in the adjunctive treatment of major depressive disorder or schizophrenia is not known. However, the drug’s efficacy may be mediated through a combination of partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, and antagonist activity at serotonin 5-HT2A receptors. Brexpiprazole exhibits high affinity (subnanomolar) for these receptors as well as for noradrenaline alpha1B/2C receptors. The drug was approved in the U.S. on July 10, 2015, as an adjunctive therapy to antidepressants in adults with major depressive disorder and as a treatment in adults with schizophrenia.

Source: Lundbeck; February 8, 2016.

Recent Headlines

Two-Thirds of U.S. Alzheimer’s Cases Are Women, And It’s Not Just Because They Live Longer
Recarbrio Should be Reserved For Limited/No Alternative Antibacterial Treatment Cases
Breast Cancer, Gastrointestinal Tumors Most Common Types
NY Hospitals Required to Implement Protocols in Suspected Cases
Presence of BOK Protein Key for Positive Treatment Response
Patient Access to Inhaler Use Data Could Improve Asthma Management
Primary Immunodeficiencies Affect 250,000 People in U.S.